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Summary
Medicines have adverse effects and the use 
of multiple medicines, polypharmacy, can 
be associated with poorer outcomes. Health 
professionals need to recognise when medicines 
should be ceased and how to deprescribe. 
Deprescribing could be considered when there is 
polypharmacy, adverse drug reactions, ineffective 
treatment, falls or when treatment goals have 
changed. if patients are slowly weaned off their 
medicines, withdrawal and rebound syndromes 
are usually not serious. A cautious approach to 
deprescribing includes two principles – stop one 
drug at a time and wean doses slowly over weeks 
and months.
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introduction
There are many evidence-based guidelines to help clinicians 
start drug treatment. There is much less evidence to guide 
clinicians about withdrawing medicines. Several terms have 
been used for ceasing medicines including deprescribing, 
withdrawal, discontinuation, pharmacolysis, untrials and 
prescription pruning. Here deprescribing is used to define the 
cessation of long-term therapy, supervised by a clinician. 
when should deprescribing be considered?
Good practice requires a regular review of a patient's medicines. 
These reviews are a good time to consider deprescribing.
Polypharmacy
The use of multiple medicines is termed polypharmacy. 
In older people it is associated with an increased risk of 
impaired physical and cognitive function, institutionalisation, 
hospitalisation and death. These associations appear to be 
independent of the underlying diseases.1 Moreover, studies 
show that reducing the number of drugs has positive outcomes 
in older people. A feasibility study to reduce polypharmacy in 
people over 70 years of age suggested that over half of their 
medicines could be discontinued. only 2% of the drugs needed 
to be restarted because the original indication re-emerged. 
overall there was improvement in cognition and the patients' 
global health.2 A review of medicine withdrawal studies in 
older people found that withdrawal was rarely associated with 
adverse effects.3 After withdrawal of antihypertensive therapy, 
many patients (20–85%) remained normotensive and withdrawal 
of psychotropic drugs was associated with a reduction in 
falls and improved cognition.3 This is further supported by a 
recent Australian pilot study which confirmed the feasibility of 
deprescribing in polypharmacy.4 
Adverse drug reactions
It is common sense to stop a drug, or to reconsider its 
benefit:harm ratio, if it causes a significant adverse reaction. For 
example, in secondary stroke prevention trials of antiplatelet 
drugs, up to one in five patients stopped treatment because 
of adverse drug reactions. Given that clinical trial participants 
do not always reflect real-life patients, it is likely that a greater 
number of patients in everyday practice will be unable to 
tolerate their medicines. Health professionals often have 
difficulty recognising adverse drug reactions, partly because 
they are reluctant and unwilling to recognise them and partly 
because the reactions can be mistaken for symptoms of disease. 
Falls and cognitive impairment are frequently secondary to 
adverse drug reactions in older people, yet are often overlooked 
as simply part of the ageing process.5 
Lack of effectiveness
For many drugs it is not possible for any individual clinician 
to assess effectiveness. This is because many drugs are 
used to prevent illness or because the number of patients 
who need to be treated for one to benefit is too large for the 
effect to be perceptible.6 However, if a drug has no effect on a 
surrogate outcome (for example blood pressure, cholesterol) 
or symptoms, then it is pointless to continue therapy because it 
accrues cost and the risk of harm without any benefit.
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Falls
Polypharmacy and drugs acting on the central nervous system 
are important risk factors for falls, increasing the risk by 
around 50%.7 A placebo-controlled clinical trial of withdrawing 
psychotropic drugs showed that falls were reduced by 66%.8 The 
number of hip fractures in Australia could be reduced by 10% 
simply by avoiding the use of benzodiazepines in older people.9 
The relationship between cardiovascular drugs and falls is less 
clear. Antihypertensive drugs are often ceased in older people 
with orthostatic hypotension and recurrent falls.
Terminal illness, dementia or frailty
It is important to re-evaluate the role of medicines once a 
patient has entered the terminal phases of an illness, become 
frail or developed disabling dementia, as there should be 
a shift in treatment goals. Many preventive therapies such 
as medicines used to treat hypertension, osteoporosis and 
hyperlipidaemia take many months and even years before their 
benefit is established. They have limited value in patients with 
a short life expectancy. Furthermore the pharmacokinetics and 
pharmacodynamics of many medicines change with frailty or 
terminal illness and this impacts on their harm:benefit ratio. 
Deprescribing will reduce the medicine load and potential 
adverse effects, while shifting the therapeutic focus to end-of-life 
issues that are important to the patient.10 
what are the consequences of deprescribing?
Like all medical interventions, including starting medicines, 
there are potential harms and benefits in deprescribing. There 
are several possible outcomes following deprescribing.
No obvious change in clinical status
In many cases there may be no obvious change in the patient 
after deprescribing. However, patient satisfaction is often 
increased, the financial cost to the patient and the community 
is reduced and the risk of future adverse drug reactions and 
interactions is removed. 
Resolution of specific adverse drug reactions
For dose-dependent adverse drug reactions, resolution of the 
adverse effect will usually coincide with the disappearance 
of the drug from the blood (3–5 half-lives). However, in some 
situations, such as delirium, resolution may take much longer 
than expected on pharmacokinetic grounds.
Improvement in function and quality of life
In a clinical trial to reduce polypharmacy in older people, 
the patients' global assessment scale improved in 88% and 
in most patients cognitive function improved.2 A systematic 
review concluded that deprescribing can be associated 
with improvements in cognition and behaviour in patients 
with dementia, and a reduction in falls.3 Simplification of 
drug regimens might also improve adherence and reduce 
medication errors.
Withdrawal syndromes
When deprescribing is undertaken slowly and under medical 
supervision, clinically significant adverse withdrawal reactions 
are rare.2,3 Even so, clinicians should be aware of potential 
problems.
Withdrawal and discontinuation syndromes
The most common cause of discontinuation syndromes 
is the withdrawal of drugs acting on the central nervous 
system. Most general practitioners will be familiar with the 
antidepressant discontinuation syndrome commonly seen 
after ceasing selective serotonin reuptake inhibitors. The 
symptoms typically occur within one week of ceasing the 
drug. They are usually mild, and resolve over ten days or less. 
The abrupt withdrawal of benzodiazepines is associated with 
a much more serious withdrawal syndrome with confusion, 
hallucinations and seizures. Abrupt cessation of levodopa is 
associated with a serious withdrawal syndrome with features of 
the neuroleptic malignant syndrome, including severe muscle 
stiffness, autonomic instability and impaired consciousness. 
In patients who have been taking systemic corticosteroids for 
more than a few weeks, sudden cessation may sometimes 
lead to an Addisonian crisis secondary to suppression of the 
hypothalamic-pituitary-adrenal axis.11,12
Rebound syndromes
Stopping a beta blocker can be associated with rebound 
tachycardia and hypertension which may aggravate heart failure 
or ischaemic heart disease. Stopping proton pump inhibitors 
is associated with hypersecretion of acid and aggravation 
of gastrointestinal symptoms. Simple analgesics and nasal 
drops can be obtained without a prescription, but cessation 
can be respectively associated with rebound headaches and 
rhinorrhoea.12 Rebound insomnia is common after stopping 
hypnotic drugs.
Unmasking drug interactions
Pharmacokinetic interactions should be considered when 
undertaking deprescribing. For example, if omeprazole is 
ceased by a patient on a stable dose of warfarin, the INR 
may decrease because omeprazole had been inhibiting the 
metabolism of warfarin.
Reappearance of symptoms of original disease 
or risk factor
It is important not to misinterpret a rebound or withdrawal 
syndrome as a recurrence of the symptoms of the original 
disease. Surprisingly, clinical trials of drug withdrawal do not 
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show a high incidence of symptoms of the original disease or 
risk factor reappearing after treatment stops.3 However, if some 
drugs, for example immunosuppressants, are stopped abruptly 
the underlying condition may flare up.
what is the approach to deprescribing?
There is limited clinical evidence to guide deprescribing, but 
some broad principles can be applied (Fig. 1).2,4,11,12
Prepare the patient for deprescribing 
When starting a drug, explain to the patient that the outcome 
will be monitored and the drug might be ceased if there is no 
beneficial effect or a significant adverse effect occurs. Patient 
expectations can be discussed and managed at this time. This 
is particularly important for drugs which have Pharmaceutical 
Benefits Scheme (PBS) continuation criteria (for example  
cholinesterase inhibitors for Alzheimer's disease), as the 
clinician must confirm that there has been clinical improvement 
in order for PBS funding to continue.
Recognise the need for deprescribing 
The main clues that deprescribing might be useful are 
polypharmacy, adverse drug reactions (for example falls in 
older people), lack of efficacy and changes in treatment goals 
which may be secondary to the onset of terminal illness, 
dementia or frailty.
Prioritise medicines to cease or doses to 
reduce
A cautious approach is to stop or reduce the dose of one drug 
at a time. This helps to identify which drug might have been 
causing harm or, if withdrawal symptoms occur, to provide a 
guide for which drug to consider recommencing. If an adverse 
drug reaction is suspected, then the implicated drug should 
obviously be stopped first. 
If the patient is elderly and taking multiple medicines then 
there are several possible approaches to identifying the drugs 
which are suitable for deprescribing, in particular focussing on 
anticholinergic and sedating drugs.2,13,14 Reducing the dose of a 
medicine or changing it from regular to 'as needed' might also 
be an appropriate goal.
Wean or taper the dose 
In many cases, medicines can be ceased abruptly, while for 
others (beta blockers, benzodiazepines, corticosteroids, opioids, 
levodopa) sudden cessation can generate serious withdrawal 
and rebound syndromes. The duration of weaning can vary 
from days to months and is influenced by factors such as the 
drug's half-life, the availability of different dose form sizes and 
scored tablets, as well as the physiological and psychological 
responses of the patient. For psychotropic medicines, the 
overall aim might be to reduce the dose by 25% each month, 
adjusting this according to the patient's response.12,15,16 This 
Fig. 1
General approach to deprescribing
Prepare discuss deprescribing at start of therapy
recognise polypharmacy, adverse drug reactions (including falls in older people), lack of 
efficacy, and change in treatment goals, often due to the onset of terminal illness, 
dementia and/or frailty
Prioritise one medicine at a time starting with the medicine suspected of causing the 
adverse drug reaction or consider using risk assessment tools
wean always wean central nervous system-active medicines (especially benzodiazepines, 
opioids), beta blockers, corticosteroids, levodopa typically over weeks and months
Monitor withdrawal syndromes, discontinuation syndromes, rebound, recurrence of illness, 
cognition, falls and quality of life
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is a reasonably conservative regimen that would be suitable 
for most other prescription drugs if there was concern 
about withdrawal or rebound. For patients who have taken 
benzodiazepines for a long time, there might also be a benefit 
in transferring the patient to an equivalent dose of diazepam, 
because of its long half-life, then commencing withdrawal. 
However, for patients who have had a serious adverse drug 
reaction, then usually the drug should be stopped immediately.
Monitor outcomes 
If a significant withdrawal syndrome or rebound occurs, then 
the drug could be resumed. Withdrawal could be attempted 
later at a slower rate. 
Assess patients for positive outcomes of deprescribing, such 
as decreased adverse effects and improved function. These 
benefits will be important for continuing compliance with 
deprescribing. 
Conclusion
Recognising adverse outcomes or a lack of efficacy requires 
skill and diligence, particularly in older people taking multiple 
medications. However, good patient care depends upon 
the ability of prescribers to evaluate the clinical need for 
deprescribing and then undertake supervised withdrawal of 
medicines when appropriate.
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The December issue of NPS RADAR reviews the evidence 
and place in therapy for:
 asenapine (Saphris) for schizophrenia or bipolar 1 
disorder (acute mania or maintenance)
 indacaterol (onbrez), a once daily beta2-agonist for 
chronic obstructive pulmonary disease
 ticagrelor (Brilanta), an oral antiplatet for acute coronary 
syndrome
 oxycodone-with-naloxone controlled-release tablets 
(Targin) for chronic severe pain.
Read the full reviews at www.nps.org.au/radar
